Isatuximab (Sarclisa, Sanofi) in combination with pomalidomide and dexamethasone has a marketing authorisation 'for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy'.
The dosage schedule is available in the summary of product characteristics for isatuximab.
The proposed list price for isatuximab in the company submission is £506.94 for a 100‑mg vial or £2,534.70 for a 500‑mg vial. The company has a commercial arrangement. This makes isatuximab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.